PathogenDx
PrivateLast Round
Grant
Mar 1, 2021
Total Funding Raised
$12.56M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
PathogenDx operates in Healthcare & Life Sciences and is based in Scottsdale, Arizona. Its latest recorded funding round was a Grant round in March 2021.
PathogenDx is a biotechnology company that provides a DNA-based pathogen testing platform for the cannabis, agriculture, food, and human diagnostics industries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Environmental Monitoring, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PathogenDx Comparables
Compare PathogenDx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TUMI Genomics | 71% | |
| MyFloraDNA, Inc. | 71% | |
| bioMérieux | 69% |
For institutional investors. Book with your work email.
PathogenDx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 1, 2021 | ||||
| Grant | Jul 28, 2020 | ||||
| Series B | Sep 30, 2019 | ||||
| Convertible Debt | Jul 17, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PathogenDx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Biomedical Imaging and Bioengineering | Grant |
| Salveo Capital | Convertible Debt, Series B |
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| Altitude Investment Management | Series B, Convertible Debt |
| Flatiron Venture Partners | Series B |
| Advance Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 123% MoM, reaching 17K.
- Jul 26, 2026
Monthly visitors increased 215% MoM, reaching 7.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 20, 2026
PathogenDx Corporation partners with United States Department of Agriculture under a five-year CRADA to advance more precise, informative Salmonella testing across poultry, beef and pork in Arizona on Oct 20th '26.
For institutional investors. Book with your work email.
PathogenDx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PathogenDx's valuation, stock price, and market status.
Is PathogenDx a public or private company?
PathogenDx is a private company.
What is the current stock price of PathogenDx?
PathogenDx is a private company, so its shares have no public market price. Caplight tracks PathogenDx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PathogenDx worth (valuation)?
Valuation information for PathogenDx is not publicly available.
Can I buy PathogenDx stock?
PathogenDx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PathogenDx's last funding round?
PathogenDx's most recent funding round was Grant on March 1, 2021.
Who are the main investors in PathogenDx?
Key investors in PathogenDx include Altitude Investment Management, Entourage Effect Capital, The Panther Opportunity Fund.
Will PathogenDx IPO soon?
No public IPO plans have been announced for PathogenDx.
How can I track PathogenDx secondary market activity?
Caplight tracks bids, offers, and trades in PathogenDx's shares on secondary markets.